Circulating Tumor Markers for High Grade Glioma

Abramson Cancer Center at Penn Medicine1 site in 1 country30 target enrollmentApril 2013

ConditionsStage III and IV Glioma Patients

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Stage III and IV Glioma Patients
Sponsor: Abramson Cancer Center at Penn Medicine
Enrollment: 30
Locations: 1
Primary Endpoint: to identify and quantify circulating tumor markers
Status: Completed
Last Updated: 6 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to identify and quantify circulating tumor markers, which are associated with the presence of tumors. The current imaging available does not allow specificity of tumor size as it relates to pseudoprogression (a temporary enlargement or "swelling" of the tumor after treatment before it shrinks). Our hope is that CTCs will provide a more accurate description of tumor state for high grade glioma patients.

Registry

clinicaltrials.gov

Start Date

April 2013

End Date

April 2020

Last Updated

6 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Abramson Cancer Center at Penn Medicine

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients with biopsy-proven high grade glioma who are undergoing definitive radiotherapy as a part of their treatment regimen or patients with radiographic appearance of high grade glioma
•Age 18 or older
•Signed informed consent